ClinicalTrials.Veeva

Menu
S

Szpital Uniwersytecki W Krakowie | Oddzial Kliniczny Kardiologii Elektrokardiologii Interwencyjnej Nadcisnienia Tetniczego

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dexamethasone
Daratumumab
Ribavirin
Interferon
Ixazomib+Daratumumab+Dexamethasone
Cusatuzumab
D-VRd
DVd
Peginterferon
BIM 23A760

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 33 total trials

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP)...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Talquetamab
Drug: Dexamethasone

The main aim is to see how the combination of pevonedistat + venetoclax + azacitidine compares to venetoclax + azacitidine in adults recently diagnos...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Pevonedistat
Drug: Venetoclax

In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of...

Active, not recruiting
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
Drug: Cytarabine
Drug: Vincristine

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Mitomycin C
Drug: Gemcitabine

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the...

Enrolling
High-risk Transient Ischemic Attack
Acute Non-cardioembolic Ischemic Stroke
Drug: Asundexian (BAY2433334)
Drug: Placebo

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: Venetoclax

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination wi...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

Active, not recruiting
Coronary Artery Disease
Device: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Takeda logo
Bayer logo
Biogen logo
Gilead Sciences logo
H
Ipsen logo
Roche logo
Seagen logo
Shire logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems